Cilnidipine | FRC-8653 | CAS#132203-70-4 | calcium channel blocker

Cilnidipine
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 326734

CAS#: 132203-70-4

Description: Cilnidipine, also known as FRC-8653, is a calcium channel blocker. Cilnidipine is the novel calcium antagonist accompanied with L-type and N-type calcium channel blocking function. It was approved in 1995. Compared with other calcium antagonists, cilnidipine can act on the N-type calcium channel that existing sympathetic nerve end besides acting on L-type calcium channel that similar to most of the calcium antagonists.

Chemical Structure

Cilnidipine

CAS# 132203-70-4

Instruction

Theoretical Analysis

MedKoo Cat#: 326734
Name: Cilnidipine
CAS#: 132203-70-4
Chemical Formula: C27H28N2O7
Exact Mass: 492.19
Molecular Weight: 492.528
Elemental Analysis: C, 65.84; H, 5.73; N, 5.69; O, 22.74

Price and Availability

Size	Price	Availability	Quantity
1g	USD 250
2g	USD 450
5g	USD 850
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: FRC-8653; FRC 8653; FRC8653; Cilnidipine; Atelec; Cinalong; Siscard.

IUPAC/Chemical Name: (E)-Cinnamyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate

InChi Key: KJEBULYHNRNJTE-DHZHZOJOSA-N

InChi Code: InChI=1S/C27H28N2O7/c1-18-23(26(30)35-14-8-11-20-9-5-4-6-10-20)25(21-12-7-13-22(17-21)29(32)33)24(19(2)28-18)27(31)36-16-15-34-3/h4-13,17,25,28H,14-16H2,1-3H3/b11-8+

SMILES Code: O=C(C1=C(C)NC(C)=C(C(OC/C=C/C2=CC=CC=C2)=O)C1C3=CC=CC([N+]([O-])=O)=C3)OCCOC

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 492.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Kuwahara K, Kimura T. The organ-protective effect of N-type Ca(2+) channel blockade. Pharmacol Ther. 2015 Jul;151:1-7. doi: 10.1016/j.pharmthera.2015.02.001. Epub 2015 Feb 7. Review. PubMed PMID: 25659931.

2: Ando K. L-/N-type calcium channel blockers and proteinuria. Curr Hypertens Rev. 2013 Aug;9(3):210-8. Review. PubMed PMID: 24479751.

3: Homma K, Hayashi K, Yamaguchi S, Fujishima S, Hori S, Itoh H. Renal microcirculation and calcium channel subtypes. Curr Hypertens Rev. 2013 Aug;9(3):182-6. Review. PubMed PMID: 24479750; PubMed Central PMCID: PMC4033552.

4: Chandra KS, Ramesh G. The fourth-generation Calcium channel blocker: cilnidipine. Indian Heart J. 2013 Dec;65(6):691-5. doi: 10.1016/j.ihj.2013.11.001. Review. PubMed PMID: 24407539; PubMed Central PMCID: PMC3905258.

5: Xu G, Wu H, Du B, Qin L. The efficacy and safety of cilnidipine on mild to moderate essential hypertension: a systematic review and meta-analysis of randomized controlled trials in Chinese patients. Cardiovasc Hematol Disord Drug Targets. 2012 Sep;12(1):56-62. Review. PubMed PMID: 22746347.

6: Hayashi K, Homma K, Wakino S, Tokuyama H, Sugano N, Saruta T, Itoh H. T-type Ca channel blockade as a determinant of kidney protection. Keio J Med. 2010;59(3):84-95. Review. PubMed PMID: 20881449.

7: Ito Y, Araki N. [Calcium antagonists: current and future applications based on new evidence. Neuroprotective effect of calcium antagonists]. Clin Calcium. 2010 Jan;20(1):83-8. doi: CliCa10018388. Review. Japanese. PubMed PMID: 20048438.

8: Mizuta E, Hamada T, Igawa O, Shigemasa C, Hisatome I. [Calcium antagonists: current and future applications based on new evidence. The mechanisms on lowering serum uric acid level by calcium channel blockers]. Clin Calcium. 2010 Jan;20(1):45-50. doi: CliCa10014550. Review. Japanese. PubMed PMID: 20048433.

9: Hirooka Y, Sunagawa K. [Calcium antagonists: current and future applications based on new evidence. Calcium channel blockers and autonomic nervous system]. Clin Calcium. 2010 Jan;20(1):32-7. doi: CliCa10013237. Review. Japanese. PubMed PMID: 20048431.

10: Takahara A. Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release. Cardiovasc Ther. 2009 Summer;27(2):124-39. doi: 10.1111/j.1755-5922.2009.00079.x. Review. PubMed PMID: 19426250.

11: Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T. Ca2+ channel subtypes and pharmacology in the kidney. Circ Res. 2007 Feb 16;100(3):342-53. Review. PubMed PMID: 17307972.

12: Hermida RC, Smolensky MH. Chronotherapy of hypertension. Curr Opin Nephrol Hypertens. 2004 Sep;13(5):501-5. Review. PubMed PMID: 15300155.

13: Suzuki H, Kanno Y. [Diagnosis of and therapy for renal hypertension]. Nihon Naika Gakkai Zasshi. 2004 Mar 10;93(3):488-92. Review. Japanese. PubMed PMID: 15052808.

14: Uneyama H, Takahara A, Wakamori M, Mori Y, Yoshimoto R. Pharmacology of N-type Ca2+ channels distributed in cardiovascular system (Review). Int J Mol Med. 1999 May;3(5):455-66. Review. PubMed PMID: 10202175.

15: Saruta T. Current status of calcium antagonists in Japan. Am J Cardiol. 1998 Nov 12;82(9B):32R-34R. Review. PubMed PMID: 9822142.

Your view history

Cilnidipine featured